Last edition
News about "4Moving Biotech"
4Moving Biotech has completed patient enrollment in its global Phase 2a INFLAM MOTION trial, assessing the safety and efficacy of investigational therapy 4P004 for inflammatory knee osteoarthritis.
4Moving Biotech | 05/08/2026 | By News Bureau | 1428
4Moving Biotech Secures EUR 7.6M France 2030 Grant to Advance Osteoarthritis Drug
4MB's selection is a significant endorsement, granted through a rigorous, multi-stage evaluation process by leading scientific, clinical, and technological experts.
4Moving Biotech | 08/04/2025 | By Abha | 306
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy